BOXED WARNING Suicidality: increased risk of suicidal thinking/behavior in children, adolescents, and young adults. Not approved in pediatric patients.
FDA dosing
Population
Start
Target
Max
Major depressive disorder
Adults
75 mg/day divided BID–TID (with food)
Up to 225 mg/day
375 mg/day (severely depressed inpatients)
Titration Increase by up to 75 mg/day at intervals of no less than 4 days.
Renal Reduce total daily dose by 25% (mild–moderate, GFR 10–70); by 50% for hemodialysis.
Hepatic Reduce total daily dose by 50% (mild–moderate impairment); may need greater reduction in cirrhosis.
Instructions
Take with food
Administer in divided doses (2–3 times daily)
Taper gradually rather than abruptly stopping
Available strengths
tab 25, 37.5, 50, 75, 100 mg
Contraindications
MAOIs (for psychiatric disorders) concomitantly, within 7 days after stopping venlafaxine, or within 14 days of stopping an MAOI; do not start in patients treated with linezolid or IV methylene blue
Cautions
Serotonin syndrome
Increased blood pressure
Increased heart rate
Discontinuation symptoms
Activation of mania/hypomania
Adverse reactions
Nausea
Somnolence
Dry mouth
Dizziness
Sweating
Nervousness/anxiety
Constipation
Anorexia
Abnormal ejaculation/impotence
Tremor
Pregnancy No clear malformation risk; third-trimester exposure can cause neonatal complications (SSRI/SNRI class).
Defining liabilityHypertension and discontinuation are common concerns; overdose can cause seizures, serotonin toxicity and cardiotoxicity.
Serotonin and MAOI
Provisional washout figures
SRI significance3 / 4
MAO-A inhibition0 / 4
Serotonin release0 / 4
Elevating mechanismSRI
Non-elevating actionNone recorded
Exposure dependenceTherapeutic exposure; severe toxicity requires meaningful MAO-A inhibition
Washout BEFORE an MAOI7 days
Evidence confidenceHigh
InterpretationClinically significant SRI. A second SRI generally represents therapeutic duplication/additive adverse effects, not the classic life-threatening interaction.